Title : Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.

Pub. Date : 2019 Dec

PMID : 31766918






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 These findings have been integrated in recent guidelines which now recommend prescribing (when initial metformin monotherapy fails) a glucagon-like peptide-1 receptor agonist or a sodium/glucose co-transporter-2 inhibitor with clinical trial-confirmed benefit in patients with diabetes and atherosclerotic cardiovascular disease, and a sodium/glucose co-transporter-2 inhibitor in such patients with heart failure or chronic kidney disease at initial stages. Metformin glucagon like peptide 1 receptor Homo sapiens